Full-Time

Clinical Laboratory Scientist I

Posted on 3/6/2025

Exact Sciences

Exact Sciences

5,001-10,000 employees

Biotechnology company for cancer detection and prevention

Compensation Overview

$42k - $67kAnnually

+ Bonus + Company Stock

Entry, Junior

No H1B Sponsorship

Madison, WI, USA

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Requirements
  • Associate degree in a laboratory science (chemical or biological science) or medical laboratory technology from an accredited institution or equivalent laboratory training and experience as defined: 60 semester hours or equivalent from an accredited institution that, at a minimum, includes either 24 semester hours of medical laboratory technology courses, OR 24 semester hours of science courses that include six semester hours of chemistry, six semester hours of biology, and 12 semester hours of chemistry, biology, or medical laboratory technology in any combination.
  • Authorization to work in the United States without sponsorship.
  • Demonstrated ability to perform the Essential Duties of the position with or without accommodation.
  • Professional working knowledge of local, state, and federal laboratory regulations.
Responsibilities
  • Perform moderate and highly complex laboratory tests, procedures, and analyses according to the laboratory’s standard operating procedures.
  • Perform, review, and document laboratory quality control procedures.
  • Operate, maintain, and troubleshoot laboratory equipment.
  • Prepare reagents required for laboratory testing.
  • Identify and troubleshoot basic problems that adversely affect test performance and/or laboratory operations.
  • Achieve and maintain competency on laboratory tasks.
  • Assist with mentoring new laboratory personnel on current and new procedures, as needed.
  • Maintain sufficient inventory of laboratory supplies for daily operations.
  • Participate in testing and validation of new laboratory equipment and procedures, as needed.
  • Maintain stringent standards for quality, identifying any issues which might adversely impact the quality of test results and/or employee safety, and communicating these to the appropriate management representatives as necessary for resolution.
  • Manage daily test processing needs along with project needs in a high quality, efficient and effective manner.
  • Communicate effectively with ability to maintain open communication with internal employees, managers, and customers, as needed.
  • Participate in quality assurance and inspection preparation activities.
  • Integrate and apply feedback in a professional manner.
  • Participate in continuing education and staff meetings. Responsible for own professional development.
  • Meet productivity and TAT expectations.
  • Work as part of a team.
  • Be flexible with tasks and schedules.
Desired Qualifications
  • Bachelor's degree in a chemical, biological or clinical laboratory science or medical technology from an accredited institution.
  • Experience in molecular biology techniques and principles.

Exact Sciences focuses on the early detection and prevention of cancer through advanced diagnostic tests. Their products are designed to identify cancer at its earliest stages, which helps healthcare providers make informed treatment decisions. The company operates globally, serving healthcare providers, patients, and research institutions in the medical diagnostics market. Unlike many competitors, Exact Sciences emphasizes a comprehensive approach that includes not only the development and sale of cancer screening tests but also support for patients and healthcare professionals. The main goal of Exact Sciences is to reduce the burden of cancer by providing effective solutions for early detection and treatment guidance.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Madison, Wisconsin

Founded

1995

Simplify Jobs

Simplify's Take

What believers are saying

  • Increasing adoption of liquid biopsy tests boosts Exact Sciences' non-invasive cancer detection.
  • Partnership with Flatiron Health accelerates clinical evidence generation for MRD testing.
  • Expansion of telemedicine services increases access to Exact Sciences' diagnostics.

What critics are saying

  • Rapid MRD testing evolution may outpace Exact Sciences' current capabilities.
  • Recent 11% stock drop suggests potential financial or operational issues.
  • Blood-based colorectal cancer test development may face regulatory hurdles or competition.

What makes Exact Sciences unique

  • Exact Sciences focuses on early cancer detection and prevention through innovative diagnostics.
  • The company partners with tech firms to leverage big data in cancer research.
  • Exact Sciences integrates AI in diagnostics, enhancing accuracy and speed in cancer detection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

Parental Leave

401(k) Retirement Plan

Wellness Program

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Business Wire
Mar 12th, 2025
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner

MADISON, Wis.-(BUSINESS WIRE)-Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2025 Gallup Exceptional Workplace Award (GEWA), marking the second year in a row the company has received this prestigious recognition.

Hit Consultant
Feb 4th, 2025
Flatiron Health And Exact Sciences Partner To Accelerate Clinical Evidence Generation For Mrd Testing In Oncology

What You Should Know:– Flatiron Health, a leading technology company focused on improving cancer care announced a strategic partnership with Exact Sciences, a pioneer in cancer screening and diagnostics to accelerate clinical evidence generation for Exact Sciences’ molecular residual disease (MRD) test, Oncodetect™.– The collaboration will leverage Flatiron’s innovative clinical research platform and extensive network of community oncology practices to study the test’s performance in diverse patient populations and real-world settings.Leverage Real-World Data and Community Oncology Settings to Advance Cancer CareMRD testing is a rapidly evolving field in oncology, with the potential to transform cancer care by detecting residual disease after treatment and guiding personalized treatment decisions. However, generating robust clinical evidence for MRD tests can be challenging and time-consuming.This partnership aims to address this challenge by:Leveraging real-world data: Utilizing data from Flatiron’s network of community oncology practices to generate evidence in a real-world setting.Utilizing data from Flatiron’s network of community oncology practices to generate evidence in a real-world setting. Focusing on diverse patient populations: Ensuring that the study includes a broad range of patients, including those typically underrepresented in clinical trials.Ensuring that the study includes a broad range of patients, including those typically underrepresented in clinical trials. Accelerating evidence generation: Employing a novel prospective clinical evidence generation platform and pragmatic study design to expedite the research process.First Patient EnrolledThe partnership has already achieved a significant milestone with the enrollment of the first patient in the study in under six months from conception. This rapid progress highlights the strong collaboration and commitment to execution between Flatiron Health and Exact Sciences.“Our partnership with Exact Sciences leverages Flatiron’s next-generation prospective evidence platform, which we designed to address critical evidence gaps via studies embedded into routine care, with unprecedented speed,” said Alex Deyle, general manager, Clinical Research, Flatiron Health. “Our in-house team of experts, experienced site network, fit-for-purpose research operations, and cutting-edge technology that focuses on reducing site burden, has enabled us to run more efficient and representative prospective studies.”

MarketBeat
Jan 19th, 2025
Retirement Wealth Solutions LLC Invests $327,000 in Exact Sciences Co. (NASDAQ:EXAS)

Retirement Wealth Solutions LLC invests $327,000 in Exact Sciences Co. (NASDAQ:EXAS).

Investor's Business Daily
Jan 16th, 2025
Exact Sciences Stock Drops 11% Over Four Days. 'What Is Going On?'

Notably, Exact Sciences is also working on its own blood-based test for colorectal cancer screening.

MarketScreener
Jan 6th, 2025
Exact Sciences Corporation Announces Appointment of Kim Popovits as A Class I Member of the Board

Exact Sciences Corporation announces appointment of Kim Popovits as A Class I member of the Board.

INACTIVE